Abstract library

39 results for "orr".
#1697 An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)
Introduction: Patients (pts) with advanced neuroendocrine tumors (NETs) who have failed sunitinib or everolimus have limited treatment options. Sulfatinib, a novel kinase inhibitor targeting tumor angiogenesis and immune evasion, has shown encouraging anti-tumor activity in patients with advanced NETs in a phase I study.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Jian Ming Xu
Authors:
Keywords: sulfatinib, net, orr, pfs
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
Authors:
#1719 Escalated Dose Somatostatin Analogues for Anti-Proliferative Effect in Gastroenteropancreatic Neuroendocrine Tumours (GEPNETS): A Systematic Review
Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy for well-differentiated GEPNETs. Dose escalation of SSAs is often trialled in clinical practice, but small studies have yielded mixed results.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr David Chan
Authors:
#1760 The Efficacy and Safety of Sunitinib in Patients with Advanced Well Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate
Introduction: In a pivotal phase 3 study (NCT00428597) SU demonstrated a significant increase in progression-free survival (PFS) vs placebo following early study termination.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Eric Raymond
Authors:
Keywords: pNET, survival, sunitinib
#79 PTOV-1 overexpression in neuroendocrine tumors: a new molecular marker
Introduction: PTOV-1 (Prostate Tumor Overexpressed-1) is a novel protein encoded by 12-exon gene localized in chromosome 19q.13.3. Recently identified as an androgen-induced gene, it is involved in prostate cell proliferation and in prostate human cancer. PTOV-1 expression has been demonstrated in neuroendocrine cells of normal prostate tissue. Preliminary data indicate that PTOV-1 can be related to flotilin, integrins and other cellular factors involved in cancer progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD INES DE TORRES
Authors:
#170 Swiss Neuroendocrine Tumor (SwissNET) registry: Results after 30 Months
Introduction: The Swiss registry for NETs (SwissNET) was established in 2008 to improve epidemiological data on NET patients in Switzerland. Here the results after 30 months of follow-up are presented.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Christoph Stettler
Authors:
#324 Well-differentiated Pancreatic Neuroendocrine Tumor of Uncertain Behavior: A Case Report
Introduction: A small number of Pancreatic Endocrine Tumors (PET) are well-differentiated tumors(WDET) showing benign or uncertain behavior. Prognosis mainly depends on the presence/absence of liver/bone metastasis.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Joana Couto
Authors:
#338 Pancreatic Endocrine Tumors: TNM staging and WHO Grading Relation with Prognosis
Introduction: Pancreatic endocrine tumors (PETs) are heterogeneous, rare neoplasms (large experience is unlikely). Prognostic stratification based on TNM staging and WHO grading is still under debate.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dra. Raquel G. Martins
Authors:
#397 Swiss Neuroendocrine Tumor (SwissNET) Registry: Update After Three Years
Introduction: To improve epidemiological data on patients with neuroendocrine tumors (NETs) in Switzerland, the Swiss registry for NETs (SwissNET) was established in 2008. Here we present the current state of the registry in 2011.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Christoph Stettler
Authors:
#445 Comparison of Prognostic Capacity for Overall Survival (OS) and Disease-Free Survival (DFS) of Neuroendocrine Tumors (NETs) Classifications: 2010 WHO, TNM Staging-ENETS and AJCC
Introduction: Current NETs classifications are: WHO, ENETS and AJCC. No consensus exists about which one more accurately predicts NET outcomes.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dra Nuria Mulet-Margalef
Authors: